...
首页> 外文期刊>BMC Cancer >Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy
【24h】

Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy

机译:细胞凋亡诱导的缺氧调节的碳酸酐酶IX从肿瘤细胞的胞外域脱落:对化学疗法的双刃反应

获取原文
           

摘要

Background Carbonic anhydrase IX (CA IX) is a tumor-associated, highly active, transmembrane carbonic anhydrase isoform regulated by hypoxia and implicated in pH control and adhesion-migration-invasion. CA IX ectodomain (ECD) is shed from the tumor cell surface to serum/plasma of patients, where it can signify cancer prognosis. We previously showed that the CA IX ECD release is mediated by disintegrin and metalloproteinase ADAM17. Here we investigated the CA IX ECD shedding in tumor cells undergoing apoptosis in response to cytotoxic drugs, including cycloheximide and doxorubicin. Methods Presence of cell surface CA IX was correlated to the extent of apoptosis by flow cytometry in cell lines with natural or ectopic CA IX expression. CA IX ECD level was assessed by ELISA using CA IX-specific monoclonal antibodies. Effect of recombinant CA IX ECD on the activation of molecular pathways was evaluated using the cell-based dual-luciferase reporter assay. Results We found a significantly lower occurrence of apoptosis in the CA IX-positive cell subpopulation than in the CA IX-negative one. We also demonstrated that the cell-surface CA IX level dropped during the death progress due to an increased ECD shedding, which required a functional ADAM17. Inhibitors of metalloproteinases reduced CA IX ECD shedding, but not apoptosis. The CA IX ECD release induced by cytotoxic drugs was connected to elevated expression of CA IX in the surviving fraction of cells. Moreover, an externally added recombinant CA IX ECD activated a pathway driven by the Nanog transcription factor implicated in epithelial-mesenchymal transition and stemness. Conclusions These findings imply that the increased level of the circulating CA IX ECD might be useful as an indicator of an effective antitumor chemotherapy. Conversely, elevated CA IX ECD might generate unwanted effects through autocrine/paracrine signaling potentially contributing to resistance and tumor progression.
机译:背景技术碳酸酐酶IX(CA IX)是一种与肿瘤相关的,高活性的跨膜碳酸酐酶同工型,受低氧调节,与pH值控制和粘附迁移侵袭有关。 CA IX胞外域(ECD)从肿瘤细胞表面流到患者的血清/血浆,在这里可以预示癌症的预后。我们先前显示,CA IX ECD释放是由整合素和金属蛋白酶ADAM17介导的。在这里,我们研究了在响应细胞毒性药物(包括环己酰亚胺和阿霉素)而发生凋亡的肿瘤细胞中脱落的CA IX ECD。方法流式细胞术检测细胞表面CA IX的存在与细胞凋亡的程度相关,该细胞系具有天然或异位CA IX表达。使用CA IX特异性单克隆抗体通过ELISA评估CA IX ECD水平。使用基于细胞的双荧光素酶报告基因分析评估了重组CA IX ECD对分子途径的激活作用。结果我们发现,CA IX阳性细胞亚群中凋亡的发生率明显低于CA IX阴性细胞中。我们还证明,由于ECD脱落增加,细胞表面CA IX水平在死亡过程中下降,这需要功能性ADAM17。金属蛋白酶抑制剂可减少CA IX ECD脱落,但不会降低细胞凋亡。由细胞毒性药物诱导的CA IX ECD释放与细胞存活部分中CA IX的表达升高有关。此外,外部添加的重组CA IX ECD激活了由Nanog转录因子驱动的途径,该因子涉及上皮-间质转化和干性。结论这些发现表明,循环中CA IX ECD水平的升高可能是有效抗肿瘤化疗的指标。相反,升高的CA IX ECD可能通过自分泌/旁分泌信号传导产生不良作用,从而可能导致耐药性和肿瘤进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号